Pfizer Inc - Proyeksi bathi mangsa ngarep PFE

The price trend shown below illustrates the profit dynamics of Pfizer Inc. (PFE), which stands at 16.87. The business is currently pivoting toward oncology and new assets due to declining vaccine demand. Financial stability relies on a massive drug portfolio and government contracts. Growth is accelerating through strategic alliances with research centers and biotech startups to drive innovation.

Pfizer Inc. (PFE): Bathi resik sing dikarepake saka 04.07.2022 nganti 12.11.2026

Rincian analitis perusahaan Pfizer Inc (PFE)

- kuotasi lan prakiraan analis:

Kutipan saham Pfizer Inc.|PFE - Konsensus nilai wajar

- rincian nilai pasar emiten:

Kapitalisasi pasar Pfizer|PFE - Nilai Dipunlarasaken Utang lan Kas

- indikator kapitalisasi buku:

Aset Bersih saben Siji Saham Pfizer|PFE - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku pfizer.com|PFE - Aset Agregat Perusahaan

- indikator total utang lan likuiditas perusahaan:

- data bathi resik lan rasio valuasi:

PFE - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep Pfizer Inc.|PFE - Kapitalisasi marang bathi resik|Pangali Forward P/E Pfizer|PFE - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Pfizer|PFE - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham (EPS TTM) Pfizer|PFE - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan pfizer.com|PFE - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Pfizer Inc.

Analisis wiwitan perusahaan:PFE, Pfizer Inc.

Projected earnings reflect the calculated business efficiency, stripped of historical distortions and market noise, allowing investors to assess the real potential for yield growth. An analysis of the projected profitability trajectory reveals that the impact of plant automation and the repurposing of Pfizer Inc. (PFE) capacities for oncology projects is reducing costs, which determines the fundamental value of the shares regardless of speculative volatility.

Perusahaan pesaing